FDA Approves Syfovre for Geographic Atrophy, a Potentially Blinding Form of Age-Related Macular Degeneration

If you’ve ever had to hold a restaurant menu at arm’s length and squint at it under your phone’s flashlight, you already know that aging eyes can be a handful. But for people living with geographic atrophy (GA) – an advanced, potentially blinding form of dry age-related macular degeneration (AMD) – it’s much more serious than needing stronger readers.

For decades, there was no FDA-approved treatment that could slow GA. Eye doctors could offer monitoring, lifestyle advice, and magnifiers, but not a medicine designed to slow the disease itself. That changed when the U.S. Food and Drug Administration approved Syfovre (pegcetacoplan injection) as the first treatment for geographic atrophy secondary to AMD in February 2023.

In this in-depth guide, we’ll break down what GA is, how Syfovre works, who might benefit, what side effects to know about, and how this new drug fits into real life for patients and their families.

What Is Geographic Atrophy and How Does It Relate to AMD?

Age-related macular degeneration is a common eye disease that damages the macula – the central part of the retina responsible for sharp, straight-ahead vision. There are two main types:

• Dry AMD (atrophic AMD) – more common, usually progresses slowly over years.
• Wet AMD (neovascular AMD) – less common but more aggressive, caused by abnormal blood vessels leaking under the retina.

Most people with AMD start with the dry form, which goes through early, intermediate, and late stages. Geographic atrophy is the late stage of dry AMD. It happens when patches of retinal cells and supporting tissue slowly die off, leaving well-defined “bald spots” of atrophy in the macula.

People with GA may notice:

• Missing or blank spots in the center of their vision
• Difficulty reading, especially small print
• Trouble recognizing faces
• Needing very bright light for close work

Peripheral (side) vision is often preserved, but the central vision loss can be severely disabling. GA is responsible for a large share of legal blindness related to AMD and affects about one million people in the United States and several million worldwide.

Syfovre 101: The First FDA-Approved Treatment for Geographic Atrophy

Syfovre (pronounced SIGH-fo-vree) is the brand name for pegcetacoplan, a prescription eye injection developed by Apellis Pharmaceuticals. The FDA approved Syfovre in February 2023 as the first treatment for geographic atrophy secondary to AMD.

In plain English, that means:

• It’s specifically for adults with GA caused by age-related macular degeneration.
• It’s not a cure and doesn’t restore lost vision.
• Its goal is to slow the progression of GA, helping people keep their remaining vision longer.

How Does Syfovre Work?

Syfovre targets part of the immune system known as the complement pathway. Complement proteins help defend the body against germs, but in AMD and GA, this system can become overactive and contribute to chronic inflammation and damage in the retina.

Pegcetacoplan is a complement C3 inhibitor. By blocking C3, it aims to dial down this overactive immune response and slow the chain reaction that leads to retinal cell death and expanding atrophic lesions.

How Is Syfovre Given?

Syfovre is given by intravitreal injection – a tiny injection into the vitreous, the gel-like substance inside the eye. This sounds scarier than it usually feels; the eye is numbed beforehand, and the needle is very small. Many patients describe it more as pressure than pain.

According to the FDA-approved label and professional guidance:​

• Syfovre is typically injected once every 25 to 60 days, depending on the dosing schedule chosen by the retina specialist and patient.
• Treatment is ongoing; stopping injections means losing the protective effect going forward.
• Each eye is evaluated separately – some people are treated in one eye, some in both.

Translation: this is not a “one and done” shot. It’s a long-term commitment, much like getting regular injections for wet AMD.

What Did Clinical Trials Show?

Syfovre’s approval was based on large phase 3 trials (OAKS and DERBY) that followed patients with GA over time. Key takeaways from published data and reviews include:​

• Syfovre reduced the rate of GA lesion growth compared with sham (placebo) injections.
• The effect increased with time, with greater slowing of GA progression at later time points.
• Both every-25-day and every-60-day dosing schedules showed benefit, though more frequent dosing tended to slow progression a bit more.

More recent five-year extension data from the GALE study suggest that sustained treatment can continue to slow lesion growth over the long term, reinforcing the idea that Syfovre may help people preserve functional vision for more years than they otherwise would.

However – and this is crucial – Syfovre does not reverse damage that’s already there. It aims to protect the vision a person still has, not bring back what’s lost.

Who Might Benefit from Syfovre?

Syfovre is approved for adults with geographic atrophy secondary to AMD, but not everyone with GA will choose or qualify for treatment. Factors that eye specialists often consider include:​

• Stage and location of GA – How close are the atrophic areas to the fovea (the very center of vision)? Is the other eye already severely affected?
• Current visual function – Is the person still driving, reading, or working? Slowing progression may have more impact when there’s still meaningful central vision to protect.
• Overall health and mobility – Regular clinic visits and injections require time, transportation, and stamina.
• Risk tolerance – Every eye injection carries risks; some people are more comfortable with those risks than others.

Insurers and health plans (like Aetna and others) usually require documentation confirming a diagnosis of GA secondary to AMD before covering Syfovre.

Side Effects and Safety Concerns

Like any medication, especially one injected directly into the eye, Syfovre comes with potential risks. According to prescribing information and safety summaries:​

Common Side Effects

The most frequently reported side effects (in 5% or more of patients) include:

• Eye discomfort or pain after injection
• Vitreous floaters (small moving spots in vision)
• Conjunctival hemorrhage (a small red patch on the white of the eye)
• Increased risk of developing neovascular, or wet, AMD in the treated eye

These are usually manageable, but they do need to be monitored at each visit.

Serious But Less Common Risks

Less common but serious events reported with intravitreal injections of Syfovre include:

• Endophthalmitis – a severe eye infection that can threaten vision
• Retinal detachment or retinal tear
• Severe intraocular inflammation

Reports of rare but serious inflammatory complications drew attention in 2023 and contributed to cautious discussion among retina specialists and regulators, particularly in Europe, where the drug has faced regulatory rejections so far.

Because of these risks:

• Syfovre is contraindicated in people with active eye infection or active intraocular inflammation.
• Patients are told to call their doctor right away if they notice intense eye pain, sudden vision changes, increased floaters, or flashing lights after injections.

The decision to use Syfovre should always be a shared one between patient and retina specialist, weighing the potential for slower GA progression against the burden and risks of frequent injections.

What Syfovre Can and Cannot Do

It’s easy to see the phrases “FDA-approved” and “first treatment” and imagine a miracle cure. Syfovre is an important breakthrough, but it works more like a “slow-down button” than a rewind button.

Syfovre can:

• Slow the expansion of GA lesions over time
• Help people hang onto their remaining central vision longer
• Offer, for the first time, a disease-modifying option for GA

Syfovre cannot:

• Restore dead or atrophied retinal cells
• Guarantee that you won’t lose driving or reading vision eventually
• Eliminate the need for magnifiers, good lighting, and other low-vision tools

Think of it like putting better brakes on a car going down a steep hill. You’re still going downhill, but you may get more time before you reach the bottom.

Living with GA in the Era of Syfovre

Whether or not someone chooses Syfovre, living with GA usually involves a mix of medical care, smart lifestyle choices, and practical adaptations at home. Evidence-based recommendations from eye-health organizations often include:​

• Regular visits to a retina specialist for monitoring and, if appropriate, injections.
• Smoking cessation – smoking is a major risk factor for AMD progression.
• Healthy diet and AREDS2-type supplements (for intermediate AMD, if recommended by your doctor).
• Managing systemic conditions like high blood pressure and cardiovascular disease.
• Using low-vision aids – magnifiers, high-contrast settings, large-print devices, and brighter task lighting.

Syfovre adds a new option to this toolkit. For some people, especially those who are still working, driving, or caring for others, slowing GA may be worth the extra time spent in the injection chair.

Smart Questions to Ask Your Retina Specialist

If you or a loved one has GA and you’re curious about Syfovre, here are some conversation starters:

• “Is Syfovre appropriate for the stage and pattern of my geographic atrophy?”
• “What kind of benefit can I realistically expect over the next 3–5 years?”
• “How often would I need injections, and for how long?”
• “What are my personal risk factors for complications?”
• “How will we watch for conversion to wet AMD?”
• “If I decide not to start Syfovre now, what are my other options?”

A good retina specialist will welcome these questions and help you weigh the pros and cons in the context of your daily life, not just your OCT scan.

Real-World Experiences Since Syfovre’s Approval

Statistics and trial graphs are helpful, but they don’t quite capture what adding Syfovre to the GA landscape has meant for patients and clinics. Since the drug’s approval, real-world experiences in retinal practices have highlighted a mix of hope, caution, and practical challenges.

In many clinics, the first wave of Syfovre patients were people who had been living with GA for years – often the “frequent flyers” who came to every appointment, knew their imaging scans by heart, and had been waiting impatiently for a treatment that did more than monitor the decline. For these patients, simply hearing that there was finally an FDA-approved therapy felt like a turning point.

One common theme retina specialists report is the emotional shift from “nothing can be done” to “we can at least slow this down.” Patients who had watched their reading vision shrink year after year often described a sense of relief knowing that there was now a way to push back against the disease, even if only modestly. Some people have said that starting Syfovre was less about expecting dramatic improvement and more about feeling active rather than helpless in the face of GA.

At the same time, Syfovre isn’t a carefree add-on. Clinics have had to rework schedules to accommodate another injection-based therapy alongside busy wet AMD and diabetic eye disease programs. For older adults, arranging transportation every month or two can be a bigger barrier than the injection itself. Family caregivers frequently become part of the “care team,” driving patients to appointments, helping manage calendars, and keeping track of follow-up instructions.

There’s also a learning curve in managing expectations. Some patients arrive at the first injection visit hoping their vision will be sharper by the next week. Retina specialists find themselves repeating a key message: the goal is slowing progression, not making the vision sharper tomorrow. Over time, people often shift to tracking their stability rather than looking for quick improvement – for example, noticing that they can still read large-print novels two years later, or that familiar faces at church are still recognizable.

Side effects and safety concerns show up in real-life conversations, too. News stories and online forums have discussed rare serious inflammatory events and the debates among regulators, especially in Europe. Patients bring these questions into the exam room, asking whether their personal risk is high, how the clinic monitors for complications, and what warning symptoms they should watch for. This has nudged many practices toward more detailed pre-treatment counseling and closer follow-up after the first few injections.

Financial realities also shape the experience. Even with insurance coverage, copays can be significant, and coverage policies vary. Some patients decide to treat only one eye – often the better-seeing eye – to balance cost, risk, and benefit. Others work with patient-assistance programs or foundations to make treatment more affordable. The paperwork isn’t glamorous, but for many families, it’s the difference between starting and skipping therapy.

For people who ultimately choose not to use Syfovre, the drug’s existence still changes the tone of the conversation. Knowing that research is finally delivering GA-specific treatments – and that additional drugs and technologies, from other complement inhibitors to retinal implants, are in development – can be comforting. Instead of feeling abandoned by science, patients and caregivers increasingly see GA as an active area of innovation, with Syfovre as the first big step rather than the final destination.

In short, Syfovre has not magically erased the challenges of geographic atrophy, but it has reshaped the narrative. Where GA used to be a strictly one-way street toward vision loss, there’s now a speed bump – and possibly more on the way. For many people living with GA, that’s enough to feel a little more hopeful when they sit down in the exam chair and look at the bright light yet again.

Bottom Line

The FDA approval of Syfovre for geographic atrophy marks a major milestone in eye care. For the first time, people living with this advanced form of dry AMD have an option that can slow the disease process itself. The treatment involves ongoing eye injections, carries real risks, and requires careful monitoring – but it also offers the possibility of preserving precious central vision for longer than was previously possible.

If you or someone you love has GA, the best next step is a detailed conversation with a retina specialist who knows your eyes, your health, and your goals. Syfovre isn’t right for everyone, but it’s a powerful new tool in the toolbox against a disease that once had no disease-modifying therapies at all.